Immunogenicity and safety of an intradermal boost in healthy general population; preliminary study (COVID-19)

faculty of medicine, Prince of songkla university0 个研究点目标入组 240 人2021年10月4日

概览

暂无简介。

注册库

who.int

开始日期

2021年10月4日

结束日期

2021年10月2日

最后更新

去年

研究类型

Observational

性别

All

发起方

faculty of medicine, Prince of songkla university

•1\. Thai adults aged 18\-60 years, who have been completed two\-dose regimen of inactive SARS\-CoV\-2 vaccine in the past 1 \- 3 months
•2\. The subjects are able to and willing to comply with the requirements of the clinical trial program and could complete the 3\-month follow\-up of the study.
•3\. Individuals who are in good health condition at the time of entry into the trial as determined by medical history, physical examination and clinical judgment of the investigator and meet the requirements of immunization
•4\. The subject can provide with informed consent and sign informed consent form (ICF).

•1\. Have the medical history or family history of convulsion, epilepsy, encephalopathy and psychosis.
•2\. Be allergic to any component of the research vaccines or used to have a history of hypersensitivity or serious reactions to vaccination.
•3\. Women with positive urine pregnancy test, pregnant or breast\-feeding, or have a pregnancy plan within six months of after baseline period.
•4\. Have infectious diseases, including HIV and SARS\-CoV\-2 infection.
•5\. Have history of SARS\-CoV\-2 infection
•6\. Have severe chronic diseases or condition in progress cannot be controlled. For examples, poor controlled DM and uncontrolled HT.
•7\. Have the history of urticaria 1 year before receiving the investigational vaccine.
•8\. Have known underlying diseases of thrombocytopenia or other coagulation disorders (which may cause contraindications for intramuscular injection).
•9\. Have needle sickness.
•10\. Have the history of immunosuppressive therapy, cytotoxic therapy or systemic corticosteroids